Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly Blackwell(Duke University), Joyce O’Shaughnessy(Baylor University Medical Center)
Cited by 960
Related Papers
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
|The Lancet|2011|1.1k
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
|Annals of Oncology|2021|294
Breast Carcinomas Arising at a Young Age: Unique Biology or a Surrogate for Aggressive Intrinsic Subtypes?
|Journal of Clinical Oncology|2010|269
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
|Clinical Cancer Research|2005|220
<i>PIK3CA</i> mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation
|Science Translational Medicine|2016|58